Patents by Inventor Peter Madsen

Peter Madsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240141011
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 15, 2023
    Publication date: May 2, 2024
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Publication number: 20240084277
    Abstract: The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: October 25, 2023
    Publication date: March 14, 2024
    Applicant: Novozymes A/S
    Inventors: Esben Peter Friis, Leonardo De Maria, Jasper Vind, Thomas A. Poulsen, Allan Svendsen, Steffen Danielsen, Rolf T. Lenhard, Henrik Friis-Madsen, Lars K. Skov
  • Publication number: 20240074933
    Abstract: A box (200) is disclosed.
    Type: Application
    Filed: December 20, 2021
    Publication date: March 7, 2024
    Inventor: Peter Madsen
  • Publication number: 20230192801
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: October 6, 2022
    Publication date: June 22, 2023
    Applicants: Novo Nordisk A/S, Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Patent number: 11649269
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: May 16, 2023
    Assignee: Novo Nordisk A/S
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • Patent number: 11603293
    Abstract: The present invention relates to an assembly for rotating a suspended load around a substantially vertical axis, the assembly comprising an inner rim configured to have a fixed relationship with the suspended load to be rotated, an outer rim engaging the inner rim in a manner so that the inner and outer rims are configured to perform rotational movements relative to each other during rotation of the suspended load, and a drive unit for performing the relative rotational movement between the inner and outer rims. The assembly of the present invention may be secured to a lifting yoke for lifting wind turbine related components, such as entire wind turbine towers, wind turbine tower sections, nacelles, rotor blades or containers.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 14, 2023
    Assignee: Vestas Wind Systems A/S
    Inventors: Jesper Fyhn Friis, Anders Olsen, Troels Vahle, Axel Peter Madsen
  • Patent number: 11498951
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: November 15, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen, Jeppe Sturis
  • Patent number: 11471537
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: October 18, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • Patent number: 11352406
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: June 7, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Publication number: 20220009989
    Abstract: The present invention relates to novel covalently linked bi-functional fusion proteins comprising insulin and EGF(A) analogues or derivatives thereof, and their pharmaceutical use. Furthermore, the invention relates to pharmaceutical compositions comprising such bi-functional compounds, and to the use of such compounds for the treatment or prevention of medical conditions relating to diabetes and dyslipidaemia associated with diabetes.
    Type: Application
    Filed: October 4, 2019
    Publication date: January 13, 2022
    Inventors: Martin Werner Borchsenius Muenzel, Susanne Hostrup, Gro Klitgaard Povlsen, Mathias Norrman, Thomas Boerglum Kjeldsen, Claudia Ulrich Hjoerringgaard, Peter Madsen
  • Publication number: 20210393745
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to a novel Fc fragment, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: October 9, 2019
    Publication date: December 23, 2021
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Zhaosheng Lin, Yuanyuan Zhang, Zhe Wan
  • Publication number: 20210179685
    Abstract: The present invention is in the therapeutic field of drugs for medical conditions relating to diabetes. More specifically the invention relates to insulin analogues of human insulin. The invention provides pharmaceutical compositions comprising such insulin analogues and the uses if the such analogues for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: December 10, 2020
    Publication date: June 17, 2021
    Inventors: Frantisek Hubalek, Mathias Norrman, Helle Birk Olsen, Peter Madsen, Thomas Boerglum Kjeldsen
  • Publication number: 20200283493
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: March 25, 2020
    Publication date: September 10, 2020
    Inventors: Peter Madsen, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Publication number: 20200261595
    Abstract: This invention is in the field of protein conjugates. More specifically the invention relates to oligomer extended insulins with covalently attached Fc monomer polypeptides, for use in the treatment of a metabolic disorder or condition, and to methods of producing such oligomer extended insulin-Fc conjugates. The invention also relates to novel Fc fragments, to intermediate products, and to the use of such intermediate products in processes for the synthesis of the oligomer extended insulin-Fc conjugates of the invention. Finally the invention provides pharmaceutical compositions comprising the oligomer extended insulin-Fc conjugates of the invention, and relates to the use of such compositions for the treatment or prevention of medical conditions relating to metabolic disorders or conditions.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 20, 2020
    Applicant: Novo Nordisk A/S
    Inventors: Tina Moeller Tagmose, Peter Madsen, Thomas Boerglum Kjeldsen, Lone Pridal, Leonardo De Maria, Zhaosheng Lin, Zhe Wan, Yuanyuan Zhang, Lennart Lykke, Martin Werner Borchsenius Muenzel, Janos Tibor Kodra
  • Publication number: 20200087122
    Abstract: The present invention relates to an assembly for rotating a suspended load around a substantially vertical axis, the assembly comprising an inner rim configured to have a fixed relationship with the suspended load to be rotated, an outer rim engaging the inner rim in a manner so that the inner and outer rims are configured to perform rotational movements relative to each other during rotation of the suspended load, and a drive unit for performing the relative rotational movement between the inner and outer rims. The assembly of the present invention may be secured to a lifting yoke for lifting wind turbine related components, such as entire wind turbine towers, wind turbine tower sections, nacelles, rotor blades or containers.
    Type: Application
    Filed: December 18, 2017
    Publication date: March 19, 2020
    Inventors: Jesper Fyhn Friis, Anders Olsen, Troels Vahle, Axel Peter Madsen
  • Publication number: 20190112348
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 18, 2019
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Patent number: 10259856
    Abstract: Novel acylated insulin analogues exhibiting resistance towards proteases can, effectively, be administered pulmonary or orally. The insulin analogues contain B25H and A14E or A14H.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: April 16, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Palle Jakobsen, Tina Moeller Tagmose, Tine Glendorf, Janos Tibor Kodra, Patrick William Garibay, Jacob Sten Petersen
  • Publication number: 20190010206
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: August 24, 2016
    Publication date: January 10, 2019
    Inventors: Peter Madsen, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Publication number: 20180305431
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: August 24, 2016
    Publication date: October 25, 2018
    Inventors: Peter Madsen, Anthony Murray, Martin Muenzel, Claudia Ulrich Hjoerringgaard, Susanne Hostrup, Tine Glendorf, Mathias Norrman, Christian Fledelius
  • Publication number: 20180244743
    Abstract: The present invention is in the therapeutic fields of drugs for medical conditions relating to diabetes. More specifically the invention relates to novel acylated derivatives of human insulin analogues. The invention also provides pharmaceutical compositions comprising such insulin derivatives, and relates to the use of such derivatives for the treatment or prevention of medical conditions relating to diabetes.
    Type: Application
    Filed: August 24, 2016
    Publication date: August 30, 2018
    Inventors: Peter Madsen, Claudia Ulrich Hjoerringgaard, Martin Muenzel, Susanne Hostrup, Christian Fledelius